| Code | CSB-RA853495MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to ianalumab, designed to specifically target TNFRSF13C, also known as BAFF receptor (BAFF-R) or BR3. TNFRSF13C is a type III transmembrane protein expressed predominantly on B cells that serves as the primary receptor for B-cell activating factor (BAFF). This interaction is critical for B-cell maturation, survival, and homeostasis. Dysregulation of the BAFF/BAFF-R pathway contributes to autoimmune diseases including systemic lupus erythematosus, Sjögren's syndrome, and rheumatoid arthritis, where excessive B-cell activation and autoantibody production drive pathology.
Ianalumab is a clinical-stage therapeutic antibody that blocks BAFF binding to TNFRSF13C, leading to selective B-cell depletion while preserving plasma cells. This biosimilar provides researchers with a valuable tool for investigating BAFF-R-mediated signaling pathways, studying B-cell biology, and exploring therapeutic mechanisms in autoimmune disease models. The antibody enables examination of B-cell dependent immune responses and facilitates preclinical research into BAFF-R targeted interventions.
There are currently no reviews for this product.